Achari Ventures Holdings I filed a prospectus for the issuance of up to 17.6 million shares at $10 each as consideration for merging with Vaso. A shareholder meeting for the vote has not yet been published.
The target is a diversified medical technology company with several specialties: managed IT systems and services, including healthcare software solutions and network connectivity services; professional sales services for diagnostic imaging products; and design, manufacture and sale of proprietary medical devices.
The merger was announced in December at a pro forma equity value of approximately $176 million.
If approved, Vaso stock and warrants are expected to list on the Nasdaq under the ticker symbols VASO and VASOW. Read more.
